**10. CoviShield - Oxford/AstraZeneca vaccine (AZD1222)**

Serum Institute of India's COVID-19 vaccine, called Covishield, is a version of the Oxford-AstraZeneca vaccine that manufacturers in India produce locally. (Covishield) has a favorable benefit-risk profile, with remarkable potential to prevent infections and diminish mortality worldwide [53]. It was proved that might protect people from various SARS-CoV-2 variants. The vaccine efficacy is found to be 95% of recipients and stop the disease progression in those infected after vaccination. In phase 3 clinical trial, they demonstrated that the AZD1222 vaccine was tolerable and successful in suppressing clinical symptoms and severe infection across different ethnic groups that recruited older individuals [54].
